SEC Company Response from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — May 14, 2020
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: May 14, 2020 · CIK: 0001534120 · Accession: 0001628280-20-007779
AI Filing Summary & Sentiment
File numbers found in text: 333-238197
Show Raw Text
CORRESP 1 filename1.htm Document 540 Gaither Road, Suite 400 Rockville, MD 20850 May 14, 2020 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Tim Buchmiller Re: Cerecor Inc. Registration Statement on Form S-3 Filed May 12, 2020 File No. 333-238197 Ladies and Gentlemen: Cerecor Inc., a Delaware corporation (the “Registrant”), hereby requests that the Securities and Exchange Commission take appropriate action to make the Registration Statement on Form S-3 (File No. 333-238197) effective as of 4:05 p.m. Eastern Time, Monday, May 18, 2020, or as soon thereafter as practicable. The Registrant respectfully requests that its legal counsel be notified when this request for acceleration has been granted by contacting via telephone call or email, Andrew J. Gibbons (Tel: 919-786-4038; E-mail: agibbons@wyrick.com). The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement. Very truly yours, CERECOR INC. By: /s/ Christopher Sullivan Name: Christopher Sullivan Title: Interim Chief Financial Officer